Tyra Biosciences Announces Late-Breaking Poster Presentation on TYRA-300 Preclinical Results at ENDO 2025

Group 1 - Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation precision medicines targeting FGFR biology [4] - The company announced that a late-breaking abstract for TYRA-300 has been accepted for presentation at The Endocrine Society's Annual Meeting (ENDO 2025) [1] - TYRA-300 is an investigational, oral, FGFR3-selective inhibitor currently in development for cancer and skeletal dysplasia, with interim clinical proof-of-concept results in metastatic urothelial cancer [2][4] Group 2 - The planned clinical development for TYRA-300 includes three Phase 2 clinical trials: SURF302 for intermediate risk non-muscle invasive bladder cancer, BEACH301 for pediatric achondroplasia, and SURF301 for metastatic urothelial cancer [2][4] - Tyra Biosciences utilizes its in-house SNÅP platform for rapid and precise drug design, which helps predict genetic alterations that may cause resistance to existing therapies [4] - The company is also developing additional investigational drugs, including TYRA-200 and TYRA-430, targeting various FGFR-related cancers [4]